Breaking AI & Tech News Analyzed

Court Blocks Trump's Transgender Military BanA United States court of appeals has ruled that a policy under President Donald Trump to expel transgender troops from the military was a violation of the Constitution. Monday's decision was a split one among the three-judge panel of the US appeals court for the District of Columbia.One judge, Robert Wilkins, an appointee of former Democratic President Barack Obama, upheld a lower court ruling rejecting the Trump administration's policy as it pertains to already enlisted service members. A second judge – Judith Rogers, who was picked by former Democratic President Bill Clinton – agreed with his opinion, but only in part. She felt it should extend to those who seek to enlist, too.And the third judge, Trump pick Justin Walker, issued a dissent questioning the court's ability to second-guess US military policy.Origins of Trump's Controversial PolicyThe case focused on one of the earliest actions Trump took during his second term in office. On January 27, 2025, a week after his second inauguration, Trump issued an executive order called "Prioritizing Military Excellence and Readiness".In it, he denounced the US armed forces as having been infiltrated with "radical gender ideology". He proceeded to describe transgender people as unfit for service for embracing a "false 'gender identity'"."A man's assertion that he is a woman, and his requirement that others honor this falsehood, is not consistent with the humility and selflessness required of a service member," Trump wrote.The executive order became the basis for a 13-page Pentagon memorandum, issued in February 2025 under Defense Secretary Pete Hegseth. It declared that any service member who has "symptoms" of gender dysphoria, or who has used hormone therapy or surgery to affirm their gender, would be "disqualified from military service".Military Service Record of Transgender PlaintiffsIn Monday's ruling, Wilkins described the policy as blatantly discriminatory. The policy, he wrote, "appears to be driven by the bare desire to harm a politically unpopular group: persons who identify as transgender"."To add insult, the President labeled transgender persons as dishonorable, undisciplined, arrogant, selfish liars," Wilkins added, pointing to the executive order.He pointed out that the transgender plaintiffs in the case had a combined 130 years of military service and had earned more than 80 commendations for their work.In the face of such evidence, Wilkins said the Trump administration had "forfeited any argument" that "retaining these service members will harm national security".Divided Rulings and Legal ImplicationsBut Wilkins stopped short of fully upholding a lower court ruling against the policy. Previously, Judge Ana Reyes had issued a temporary injunction against Trump's executive order, finding that the discrimination against transgender troops was unconstitutional.Wilkins agreed with Reyes that the Trump administration could not dismiss those already in the military's employ. But, he added, the harm was less for those seeking to enlist.Monday's ruling, therefore, strikes down the part of Reyes's injunction that would have barred the Trump administration from banning transgender people from the enlistment process.Rogers, the Clinton appointee, disagreed with that distinction. She pointed to testimony indicating that excluding transgender recruits from joining the military would deprive "our force of qualified personnel who have proven their ability to serve".Meanwhile, the dissent from the Trump appointee, Walker, hinged on his argument that the court had violated the separation of powers in the US government.Courts, he argued, should not be able to rule on the composition of the military."We have neither the expertise nor the authority to decide whether the military can exclude the plaintiffs from its ranks," Walker wrote. "The Constitution assigns that authority to Congress and the Commander in Chief."What Happens Next in the Legal BattleThe split decision is unlikely to have an immediate effect on US military policy. The appeals court has stayed the preliminary injunction from Reyes, as the legal fight continues, and last year, the US Supreme Court also halted an injunction against Trump's anti-transgender policy, in the case United States v Shilling.In a short, four-word social media post, Hegseth signalled that the Pentagon would appeal Monday's decision."See you at SCOTUS," he wrote, using the acronym for Supreme Court of the United States.But Democrats and LGBTQ+ advocates hailed the ruling as a victory against prejudice and discrimination in the Trump administration."No one who is qualified and answers the call to serve should be denied that opportunity because of who they are," US Representative John Larson of Connecticut wrote in a statement."Trump's trans military ban is discrimination — plain and simple. We'll keep fighting these attacks on our troops and all transgender Americans."

Lead: Antonio’s Raw Confession Sets a New Tone for Player Welfare TalkIn Humans Not Robots, West Ham striker Michail Antonio admits he “never thought I needed therapy” and describes how a December 2024 Ferrari crash, a broken leg and a turbulent contract saga pushed him to the brink of depression. Antonio’s Candid Revelations in the AutobiographyThe book opens with the December 2024 crash that left him with a broken leg, then moves to the emotional fallout after West Ham’s 2023 Conference League triumph over Fiorentina, where a personal row with his ex‑partner kept him from celebrating with teammates in Prague. 36‑year‑old at the time of the crashBroken leg, but no lasting physical injuryFirst major trophy for West Ham in 43 years Key Numbers Highlighting Antonio’s Career and Contract Dispute68 goals in 268 Premier League appearances – club record for West HamJoined West Ham in 2015 and became a modern club greatNegotiated a new contract in 2025 while recovering from injury; talks stalled after manager Graham Potter was replaced by Julen Lopetegui and later David Potter Impact on Club Culture and Player Mental‑Health AwarenessAntonio’s story underscores how elite clubs can overlook the psychological toll of injuries, personal crises and contract uncertainty. He credits the head physio for urging professional help, exposing a gap in standard club support structures. His criticism of co‑owner David Sullivan and former manager Graham Potter—who he says “got rid of all the leaders”—highlights a broader issue of player expendability in the Premier League. Future Outlook: What Antonio’s Disclosure Means for West Ham and the Wider GameIf clubs take Antonio’s experience as a catalyst, we may see: Increased investment in mental‑health resources for playersMore transparent contract negotiations to avoid “yo‑yo” situationsPotential shift in West Ham’s recruitment strategy, valuing player welfare alongside on‑field performance For Antonio, the next chapter could involve a continued role at West Ham if a fair deal is reached, or a move elsewhere where his mental‑health needs are better supported.

The Breakthrough in Breast Cancer TreatmentA landmark international study has revealed that millions of women with breast cancer could safely skip chemotherapy thanks to a genomic test that determines who needs the treatment and who doesn't. The randomised trial specifically examined whether the test could identify patients who would not benefit from chemotherapy, allowing them to avoid the potentially debilitating treatment without compromising their outcomes.The Scientific Evidence Behind the TestThe results of the Optima trial, which will be presented at the American Society of Clinical Oncology's annual meeting, are being hailed by experts as gamechanging. The five-year cancer-free survival rate was 93.7% in the group that skipped chemotherapy, which was statistically non-inferior to the 94.9% rate in patients randomly assigned to receive chemotherapy.The Prosigna genomic test analyzes the activity of 50 specific genes in tumor tissue to determine the molecular subtype and develops a risk of recurrence score to help doctors decide if chemotherapy is necessary. This precision medicine approach allows for personalized treatment decisions based on the unique characteristics of each patient's cancer.A Patient's Journey to Avoiding ChemotherapyKaren Bonham, a speech and language therapist from Swansea in Wales, was one of 4,429 patients with breast cancer recruited to the trial from countries including the UK, Norway, Sweden, Australia, New Zealand and Thailand. Diagnosed with cancer in 2017 at the age of 55 after routine breast screening, Bonham described the news as shocking."It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive," she said. Dreading chemotherapy, she agreed to join the Optima trial after undergoing surgery. She was only days away from starting treatment and had already cut her hair short when the results came back in September 2017.While taking a walk on a Welsh beach, Bonham received a phone call from her hospital informing her she had been allocated to the group of patients that would not be having chemotherapy. "How to describe the initial feeling? Immense relief? Like Christmas? Certainly a mixture of the two," she said.The Future of Personalized Cancer CareToday, Bonham, now 64, retired and living in Cardiff, is free of cancer, healthy and shows no signs of the disease coming back. "It is coming up to nine years since my diagnosis," she said. "I am mindful of my diagnosis, alert to potential changes in my body but do not feel defined by [it]. I walk, enjoy yoga and live well."While not every woman with breast cancer will be able to skip chemotherapy—the treatment remains necessary and important for many—the trial results suggest that genomic testing can safely identify those who can avoid it. This approach represents a significant shift toward personalized medicine in oncology, reducing unnecessary treatment and its associated side effects while maintaining excellent outcomes."I hope that the trial will bring positive patient outcomes to many," Bonham said, reflecting on the potential impact of this research on future breast cancer patients.

Scientists from University College London and partners have proved that a 50‑gene genomic test can reliably pinpoint hormone‑positive breast‑cancer patients who do not need chemotherapy, potentially sparing millions from toxic side‑effects.Optima Trial Demonstrates Genomic Test Can Identify Low‑Risk PatientsThe Optima trial enrolled 4,429 women aged 40+ across the UK, Norway, Sweden, Australia, New Zealand and Thailand. Participants were split into a standard‑care arm (chemotherapy + hormone therapy) and a test‑guided arm where treatment was decided by the genomic score.Trial Numbers Reveal Near‑Identical Survival RatesFive‑year outcomes were strikingly similar:95% of patients receiving chemotherapy remained alive and recurrence‑free.94% of patients who skipped chemotherapy (low‑score group) were also alive and recurrence‑free.The test classified patients using a score derived from the activity of 50 tumour genes, produced by Veracyte's Prosigna assay.These figures indicate that for low‑score patients, chemotherapy adds little or no survival benefit.Potential Shift in Breast Cancer Treatment GuidelinesProf Rob Stein, chief investigator, says the results “address a longstanding challenge” by moving decision‑making from clinical features to tumour biology. Health systems could see reduced drug costs, fewer hospital visits, and a dramatic drop in chemotherapy‑related toxicity.Future Adoption and Healthcare SavingsWith funding from the NIHR, Veracyte and cancer charities, the study paves the way for rapid guideline updates at bodies like ASCO and NICE. Wider implementation could translate into billions of dollars saved globally and improve quality of life for countless patients. Ongoing monitoring will confirm long‑term outcomes, but the early data suggest a new era of personalised, cost‑effective breast‑cancer care.

World Health Organization Director-General Tedros Adhanom Ghebreyesu confirmed on 31 May 2026 that five individuals infected with the rare Bundibugyo Ebola strain have recovered, including four who will be discharged today and one who left the hospital on Friday. The announcement came as the WHO opened a new treatment centre in Bunia, Ituri province, DRC.First Recoveries Confirmed in Bundibugyo Ebola OutbreakThe recoveries represent the first documented successes against a strain that has no approved vaccine or specific therapy. Doctors Without Borders (MSF) had described the situation as “deeply alarming” due to rapid case growth and diagnostic challenges.Outbreak Statistics Highlight Ongoing ThreatSuspected cases: ~1,000Suspected deaths: >220Current confirmed cases in DRC: rising rapidly across Ituri provinceCross‑border impact: Uganda reports 1 death and 9 casesThe Bundibugyo strain historically carries a case‑fatality rate of up to 50%, intensifying concerns about containment.Health System Strain and Regional Risks IntensifyLimited testing capacity and the absence of approved medical countermeasures have stretched local health infrastructure. MSF warned that the response has not yet caught up with the epidemic’s speed, and the outbreak’s proximity to the Ugandan border raises the risk of cross‑border transmission.Outlook: Vaccine Development and Containment ProspectsWhile the recoveries provide a morale boost, experts stress that sustainable control will depend on accelerated vaccine research, expanded diagnostic capacity, and coordinated regional surveillance. The WHO’s new treatment centre aims to improve patient outcomes, but long‑term containment will require international funding and rapid deployment of experimental therapeutics.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Connection to Nature As a recent study revealed almost half of UK adults now spend less than three hours a week in natural settings such as gardens, parks, fields or woods, we asked readers to tell us about what being outside means to them. Personal Stories of Healing The replies – heartfelt and passionate – came flooding in, with some admitting they just did not have the words to say how important it is. “It’s my happy place, my therapy and a reason to slow down and pause during my busy week,” wrote Hannah Powell from Perrywood garden centres. “I HAVE to look at plants every day. I notice every change in the garden. I sit facing the garden for my breakfast. I look out for nature on the way to work (recently seeing a little owl, red kites, foxes, hares, and more). It helped me get better when I had burnout and FND in London. I wouldn’t (couldn’t) be without it.” The Science Behind Nature's Benefits David Lynch esaid about his love of being outside. “Anxiety levels drop, all worldly concerns are put in perspective and [I] feel younger.” He agreed with others that there was plenty of recent science explaining the health benefits, but added: “I also read about ancient wisdom of Buddhism, which advocates solitary time in nature. All sources uphold the truth that better connection with nature brings better self-awareness and increased sensitivity to the needs of our ecosystem, plus better connection with each other.” The Impact on Mental Health Isabel Romaniw, who is working towards becoming a forest bathing guide, wrote passionately about the basic human need to be outside and to connect with nature. “We are animal, a simultaneously ordinary and yet utterly remarkable part of the great, miraculous tapestry of life on Earth. We have done much to shape our world and influence the fates of almost all other species we share our world with, but we must remember that we are but a tiny chapter, perhaps a footnote, in the ongoing story of the universe, in order to start to heal the damage and repair our relationships with ourselves, with each other, with our other-than-human kin, and with our one precious home.” For Romaniw, as for many others, our disconnection with nature is closely linked to “the worsening physical, mental and spiritual health crises that seem to be going on”. Cherished Memories of Nature Many of you had wonderful memories of times outside. “I was a sickly, pasty, shy, anxious kid,” wrote Mat Jordan. “In the early 70s my parents couldn’t afford to take us to the seaside one year so we went camping in the Peak District instead. It was a revelation. I absolutely loved it. The landscape and dry-stone walls of the white peak are still a favourite, although I spent some years in my 20s living in the Lake District too. One of my favourite memories is driving out of Sheffield into the Peaks with my then baby son to get him to fall asleep and still being awe-struck at the beauty on our doorstep.”

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Lead: Graduation Celebration Amidst Economic DespairAt Bethlehem University, the sound of drums and whistles fills the air as final-year students celebrate their graduation. Families gather with flowers and phones, but beneath the festivities, a quiet dread prevails among graduates facing a collapsed job market.The Event Details: Education as a Broken PromiseFor decades, education has been one of the few paths Palestinians could rely on for stability and social mobility despite occupation and political instability. Now, many young graduates say that promise is collapsing.Siwar Abu Kamal, 21, a business student, reflects: "The older you get, the more reality shocks you." Her classmate Christy Abu Mahour, 21, adds: "We don't get the same options as everyone else."Reaching graduation takes more than academic perseverance. Students face military raids, road closures, unpredictable commutes, and classes moving online with each political escalation. Many have also worked to fund their degrees as financial pressure at home mounted.The Data Analysis: Unemployment Crisis in NumbersNearly 40 percent of young Palestinians in the occupied West Bank holding at least a diploma are unemployed, according to figures cited by the Palestine Economic Policy Research Institute (MAS).Overall unemployment has more than doubled since October 2023, peaking at 35.2 percent in early 2024 and sitting at 27.5 percent by the end of 2025. Israel's indefinite freeze of work permits for 115,000 Palestinians from the West Bank who worked in Israel has compounded the crisis.In the Bethlehem governorate alone, about 1,080 people holding at least a master's degree have left in the past three years, according to former mayor Maher Canawati.The Impact Analysis: Economy That Cannot Absorb TalentEvery year, Palestinian universities produce tens of thousands of graduates, but the economy has not been growing to meet them. Salsabyl Salama, 25, graduated in 2023 with a degree in physiotherapy but now works at a supermarket checkout. "It's not what I dreamed of," she says, "but it allows me to depend on myself."The public sector, once seen as a stable path, has become increasingly unreliable. Since 2021, the Palestinian Authority has struggled to pay salaries as Israel withholds Palestinian tax revenues. By mid-2025, public sector workers had accumulated billions of dollars in unpaid wages, according to the World Bank.Decades of dependence on jobs in Israel left the Palestinian economy too weak to absorb graduates locally, effectively turning Palestinian workers into "political hostages," tying their livelihoods to volatile Israeli security considerations rather than sustainable domestic growth.The Prediction: Exodus of Talent and ResilienceThe crisis is driving a growing number of Palestinians to leave the country altogether. "All of the brains are leaving," says Canawati. "Getting immigration papers and leaving Palestine without those who can actually build the economy, build the country."For those who stay, leaving their field entirely is sometimes the only option. Salama has enrolled in a pastry chef course alongside her job at a grocery store, an attempt to rebuild some sense of direction. "I was beginning to lose hope, but hope came back to me," she says.Despite the challenges, graduates maintain resilience. "There is happiness here," says Abu Kamal over the sound of drums and cheering. "We hold on to hope because people deserve happiness."